Jump Financial, LLC Arcus Biosciences, Inc. Transaction History

Jump Financial, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$14.83 - $20.18 $477,377 - $649,594	32,190 New	32,190 $607,000
Q2 2023 Oct 21, 2024	BUY	$16.97 - $22.03 $1.08 Million - $1.41 Million	63,921 New	63,921 $1.3 Million
Q2 2023 Aug 07, 2023	BUY	$16.97 - $22.03 $1.08 Million - $1.41 Million	63,921 New	63,921 $1.3 Million
Q1 2022 May 12, 2022	SELL	$28.92 - $41.83 $282,924 - $409,222	-9,783 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$31.38 - $48.47 $306,990 - $474,182	9,783 New	9,783 $396,000
Q1 2021 May 17, 2021	SELL	$26.16 - $41.39 $454,111 - $718,489	-17,359 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$17.0 - $32.36 $47,192 - $89,831	-2,776 Reduced 13.79%	17,359 $451,000
Q3 2020 Nov 13, 2020	BUY	$17.14 - $25.47 $345,113 - $512,838	20,135 New	20,135 $345,000

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.02B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.